Bio-thera and dr. reddy's execute exclusive commercialization agreement for bat2206, a proposed stelara® biosimilar, and bat2506, a proposed simponi® biosimilar, for southeast asia

Guangzhou, china and hyderabad, india , march 27, 2025 /prnewswire/ -- bio-thera solutions (688177:sh; "bio-thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and dr. reddy's laboratories sa, wholly-owned subsidiary of dr. reddy's laboratories ltd. (bse: 500124 | nse: drreddy | nyse: rdy | nseifsc: drreddy, along with its subsidiaries hereafter referred to as "dr. reddy's"), announce today they have reached commercialization and license agreements for bat2206, a proposed stelara® biosimilar, and bat2506, a proposed simponi® biosimilar.
RDY Ratings Summary
RDY Quant Ranking